BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 30, 2007
 |  BioCentury  |  Strategy

Amarin forced to rethink

The failure of Amarin Corp. plc's Miraxion in two Phase III trials in Huntington's disease has forced a major reshuffling of priorities. While the company says it's too early to drop Miraxion, it will accelerate work on two preclinical programs and its CNS delivery platform.

Miraxion is a semi-synthetic, highly purified derivative of the omega III fatty acid (all-cis)-5,8,11,14,17-eicosapen-taenoic acid (ethyl-EPA) that acts to inhibit phospholipase A2. The target enzyme is thought to degrade nerve cell membranes by initiating the release of free fatty acids from cell membranes, upsetting the delicate balance between fatty acids and phospholipids necessary for membrane fluidity. Increased phospholipase A2 activity also has been associated with apoptosis.

According to CEO Rick Stewart, Miraxion's mechanism of action is believed to involve the replenishment of the lipid bi-layer, which the company hypothesizes could prevent or slow progression from neuronal dysfunction to apoptosis.

"Until last week, all indications were that this...

Read the full 751 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >